News

New guidelines presented at the 2024 American College of Rheumatology (ACR) Convergence address the critical need for effective lupus...

Vir Biotechnology announced a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) regarding...

Incyte, a global biopharmaceutical company, has temporarily halted enrollment in its Phase 2 clinical trial evaluating MRGPRX2 (INCB000262) for...

Adicet Bio has initiated a Phase 1 clinical trial for ADI-270, a novel cancer therapy. This trial focuses on...

Silence Therapeutics recently unveiled end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, an siRNA therapy, in individuals...

Innate Pharma announced preclinical data demonstrating the potential of IPH6501, its proprietary NK cell engager, for B-cell non-Hodgkin lymphoma...

Boston Pharmaceuticals announced positive Phase 2 study results for efimosfermin alfa, a long-acting FGF21 analogue, in patients with stage...

Vir Biotechnology announced positive end-of-treatment results from Part B of its MARCH Phase 2 clinical study. This study is...

Bristol Myers Squibb (BMS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

Gilead Sciences recently released promising interim data from the Phase 3 ASSURE study on Livdelzi (seladelpar) for primary biliary...